| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$196.5M | ROE | −81.90% |
| Net Margin | — | ROIC | −116.62% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Annexon, Inc. is a clinical-stage biopharmaceutical company developing medicines for inflammatory-related diseases. Its candidates include Tanruprubart, a monoclonal antibody studied for Guillain-Barré syndrome, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, an antigen-binding fragment in development for geographic atrophy; ANX1502, an oral small molecule inhibitor for autoimmune indications; and ANX009, a C1q-blocking Fab for lupus nephritis.
| Market Cap | $770.9M | Trading Days | 1361 |
| 52W High | 7.18 |
| 52W Low | 2.03 |
| % Off High | −30.78% |
| YTD | −1.00% | 1Y | 99.60% |
| 3Y | 54.83% | 5Y | −77.25% |
| Since incept. (ann.) | −29.47% |
| Ann. Volatility (1Y) | 79.89% | Ann. Volatility (3Y) | 85.78% |
| Sharpe (1Y) | 1.26 | Sharpe (3Y) | 0.59 |
| Max Drawdown (1Y) | −35.06% | Max Drawdown (3Y) | −82.33% |
| Beta (3Y, vs SPY) | 2.36 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| MNPR | Monopar Therapeutics | $730.8M | — |
| OMER | OMEROS CORP | $816.4M | — |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| XOMA | XOMA Royalty Corp | $722.3M | 27.5 |
| CMMB | Chemomab Therapeutics Ltd. | $822.8M | 79.4 |
| KURA | Kura Oncology, Inc. | $826.5M | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $712.3M | 2.0 |
| CLYM | Climb Bio, Inc. | $703.7M | — |
| CTMX |
| CytomX Therapeutics, Inc. |
| $701.0M |
| — |
